US and EU confirm tariff deal on pharmaceuticals, generics largely exempt
The US and EU have confirmed a trade agreement involving US import tariffs of 15% on prescription medicines. Generics manufacturers will face a maximum tariff of 2.5%.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1324 entries already.
Entries by Thomas Gabrielczyk
Mallia Aesthetics is about to launch MAL-838
/in News/by Thomas GabrielczykGermany’s Mallia Aesthetics GmbH has announced the achievement of key regulatory milestones in preparation for the market launch of its sCD83-based hair growth stimulant, MAL-838, later this year.
BioMed X and Novo Nordisk collaborate to optimise oral peptide therapeutics
/in News/by Thomas GabrielczykNovo Nordisk has entered a collaboration with research institute BioMed X in an effort to regain market position lost to leading competitors in diabetes and obesity treatment. The partnership is focused on improving the low bioavailability of orally administered peptide-based medicines.
Anocca raises €38.4m to advance TCR-T leads vs. pancreatic cancer
/in News/by Thomas GabrielczykSwedish immunoncology specialist Anocca AB has raised SEK440m (€38.36m) ahead of enrolling pancreatic cancer patients in a Phase I umbrella trial evaluating the safety of its T-cell receptor-engineered T cell (TCR-T) programmes ANOC-001, ANOC-002 and ANOC-003.
Merck and mantro enter the foodtech market
/in News/by Thomas GabrielczykThe laboratory division of Merck KGaA has, in partnership with the German company builder Mantro GmbH, established EdiMembre Inc, a Massachusetts-based company set to deploy Merck’s technologies for the production of structured meat alternatives – primarily Merck’s edible membranes.
Trump delays 250% tariffs on non-U.S. pharmaceuticals
/in News/by Thomas GabrielczykU.S. President Donald Trump’s announcement regarding new tariffs on pharmaceutical goods imported into the United States has been delayed. Despite the President’s threat early last week that a tariff disclosure would come “within the next week or so,” the much-anticipated announcement is now expected to be “weeks away,” according to a report from Reuters citing industry and government sources.
CPTx and NanoCell Therapeutics secure Eurostars grant to develop non-viral in-vivo CAR-T therapies
/in News/by Thomas GabrielczykGerman CPTx GmbH, its CDMO Gxstrands, and the US start-up NanoCell Therapeutics have been awarded a Eurostars grant for their QUIET-CAR project, funded through the EU’s Horizon Europe programme and the Eureka Network. The focus of the project will be on the development of scalable in-vivo CAR-T therapies against cancer and autoimmune diseases.
Pilatus Biosciences Enters Clinical Collaboration with Roche
/in News/by Thomas GabrielczykPilatus Biosciences AG, a Swiss biotechnology company headquartered in Epalinges with operations in the United States and South Korea, has entered into a clinical trial collaboration with Roche AG. As part of the agreement, Roche will provide its PD-L1 immune checkpoint inhibitor atezolizumab for use in a Phase I study evaluating the combination of atezolizumab with Pilatus’s investigational CD36 inhibitor, PLT012, in patients with hepatocellular carcinoma (HCC).
Bayer announces US$1.3bn oncology deal with Kumquat Biosciences
/in News/by Thomas GabrielczykBayer AG’s Pharmaceuticals division in Berlin has expanded its oncology pipeline through a licensing and collaboration agreement with US-based Kumquat Biosciences Inc., which may yield up to US$1.3bn in total consideration. Should Kumquat successfully complete its high-risk Phase Ia clinical study targeting the common KRAS G12D mutation, Bayer will assume responsibility for further development and global commercialisation of the candidate.
IO Biotech’s cancer jab falls short in Phase 3, but Danish firm still eyes FDA approval
/in News/by Thomas GabrielczykIO Biotech has published top-line results from its pivotal Phase 3 trial evaluating the therapeutic cancer vaccine IO102-IO103 (Cylembio) in combination with pembrolizumab in patients with advanced melanoma. While the combination achieved a notable improvement in progression-free survival (PFS), the study narrowly missed its predefined statistical threshold for significance.